Quantitative Investment Management LLC acquired a new stake in Zoetis Inc. (NYSE:ZTS – Free Report) during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 45,119 shares of the company’s stock, valued at approximately $3,242,000.
Several other hedge funds and other institutional investors have also recently modified their holdings of the company. J. Stern & Co. LLP raised its position in Zoetis by 12,431.2% during the 4th quarter. J. Stern & Co. LLP now owns 24,069,492 shares of the company’s stock valued at $3,028,423,000 after purchasing an additional 23,877,416 shares during the last quarter. Norges Bank bought a new position in Zoetis in the 4th quarter worth $734,425,000. Flossbach Von Storch SE purchased a new stake in shares of Zoetis in the 2nd quarter worth about $302,601,000. BlackRock Inc. boosted its stake in shares of Zoetis by 10.8% during the 2nd quarter. BlackRock Inc. now owns 39,430,181 shares of the company’s stock valued at $2,833,453,000 after purchasing an additional 3,845,869 shares in the last quarter. Finally, Ruane Cunniff & Goldfarb L.P. bought a new stake in shares of Zoetis during the 1st quarter valued at about $286,660,000. 92.80% of the stock is owned by institutional investors.
Analyst Ratings Changes
A number of equities analysts recently issued reports on the stock. Weiss Ratings downgraded shares of Zoetis from a “sell (d+)” rating to a “sell (d)” rating in a research note on Friday, June 12th. BNP Paribas Exane reduced their target price on Zoetis from $146.00 to $110.00 and set an “outperform” rating on the stock in a report on Tuesday, August 11th. TD Cowen decreased their target price on Zoetis from $104.00 to $94.00 and set a “buy” rating for the company in a research report on Tuesday, August 25th. HSBC lowered their target price on Zoetis from $140.00 to $95.00 and set a “buy” rating for the company in a research note on Monday, July 6th. Finally, Morgan Stanley set a $85.00 price target on Zoetis in a research note on Friday, August 7th. Eight equities research analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, Zoetis has an average rating of “Hold” and an average price target of $107.43.
Zoetis Stock Performance
Shares of ZTS stock opened at $77.45 on Monday. The company has a market capitalization of $32.00 billion, a price-to-earnings ratio of 12.76, a price-to-earnings-growth ratio of 1.80 and a beta of 0.73. The company has a debt-to-equity ratio of 2.87, a quick ratio of 1.84 and a current ratio of 3.08. Zoetis Inc. has a one year low of $71.00 and a one year high of $156.49. The company’s 50-day moving average is $75.57 and its 200 day moving average is $95.40.
Zoetis (NYSE:ZTS – Get Free Report) last issued its earnings results on Thursday, August 6th. The company reported $1.87 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.85 by $0.02. The business had revenue of $2.47 billion during the quarter, compared to analysts’ expectations of $2.50 billion. Zoetis had a net margin of 27.49% and a return on equity of 74.89%. The business’s revenue for the quarter was down .2% compared to the same quarter last year. During the same period in the previous year, the company earned $1.76 earnings per share. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. Sell-side analysts expect that Zoetis Inc. will post 6.2 EPS for the current fiscal year.
Zoetis Profile
Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.
Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.
Recommended Stories
- Five stocks we like better than Zoetis
- Strike a Balance Between Growth and Stability With These 3 Names Ready to Rally
- Rubrik’s AI Security Bet Could Power the Next Leg Higher
- Apple’s Foldable iPhone Could Be a Catalyst, But Not a Cure-All
- Snowflake Is Up Nearly 50% in 2026—What Are Short Sellers Betting Against?
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS – Free Report).
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.
